Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Kennedy VE, Peretz CAC, Walia A, Chyla B, Sun Y, Hill J, Tran E, Koh AD, Ferng T, Pintar S, Jones MF, Popescu B, Lomeli I, Chehab F, Murad N, John A, Roy R, Olshen A, Berryhill CA, Davis C, Angus SP, Rivera JM, Meshulam A, Stieglitz E, Joshi S, Traer E, Dail M, Hamidi H, Altman JK, Daver N, Levis M, McCloskey J, Perl AE, Smith CC

Open source

DOI: 10.1182/blood.2025032466
Published: 2026 Sep 17
Container: Blood
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2025032466,
  title = {Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.},
  author = {Kennedy VE and Peretz CAC and Walia A and Chyla B and Sun Y and Hill J and Tran E and Koh AD and Ferng T and Pintar S and Jones MF and Popescu B and Lomeli I and Chehab F and Murad N and John A and Roy R and Olshen A and Berryhill CA and Davis C and Angus SP and Rivera JM and Meshulam A and Stieglitz E and Joshi S and Traer E and Dail M and Hamidi H and Altman JK and Daver N and Levis M and McCloskey J and Perl AE and Smith CC},
  year = {2026},
  journal = {Blood},
  doi = {10.1182/blood.2025032466},
  url = {https://doi.org/10.1182/blood.2025032466}
}

RIS

TY  - JOUR
TI  - Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
AU  - Kennedy VE
AU  - Peretz CAC
AU  - Walia A
AU  - Chyla B
AU  - Sun Y
AU  - Hill J
AU  - Tran E
AU  - Koh AD
AU  - Ferng T
AU  - Pintar S
AU  - Jones MF
AU  - Popescu B
AU  - Lomeli I
AU  - Chehab F
AU  - Murad N
AU  - John A
AU  - Roy R
AU  - Olshen A
AU  - Berryhill CA
AU  - Davis C
AU  - Angus SP
AU  - Rivera JM
AU  - Meshulam A
AU  - Stieglitz E
AU  - Joshi S
AU  - Traer E
AU  - Dail M
AU  - Hamidi H
AU  - Altman JK
AU  - Daver N
AU  - Levis M
AU  - McCloskey J
AU  - Perl AE
AU  - Smith CC
PY  - 2026
JO  - Blood
DO  - 10.1182/blood.2025032466
UR  - https://doi.org/10.1182/blood.2025032466
ER  -

APA

VE, K., CAC, P., A, W., B, C., Y, S., J, H., E, T., AD, K., T, F., S, P., MF, J., B, P., I, L., F, C., N, M., A, J., R, R., A, O., CA, B., C, D., SP, A., JM, R., A, M., E, S., S, J., E, T., M, D., H, H., JK, A., N, D., M, L., J, M., AE, P., & CC, S. (2026). Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.. Blood. https://doi.org/10.1182/blood.2025032466

Source records

pubmed · retrieved 2026-09-27T15:59:49.511Z
europe-pmc · retrieved 2026-09-27T15:59:49.538Z